By Yafo Life Sciences
December 26th, 2021 (Shanghai) — We are glad to announce that Walter Korz, the COO of WEX Pharmaceuticals Inc. and Abner Yong, the VP Finance of WEX Pharmaceuticals Inc., have been invited to showcase at ACCESS CHINA Biotech Forum during Jan 4th – Jan13th. ACCESS CHINA Biotech Forum is the largest online corporate access event between China and the western biopharma industry.
If you are interested in listening to the live event, please register at https://biotochina.org/register/
About WEX Pharmaceuticals Inc.
WEX Pharmaceuticals Inc. (WEX) is a late-stage biopharmaceutical company focused on developing Halneuron®, for the treatment of neuropathic and nociceptive pain. Halneuron is icleared by the US Food Drug Administration and Health Canada to commence pivotal Phase 3 trials for Chemotherapy-Induced Neuropathic Pain (CINP). Halneuron has also demonstrated promising clinical effects in moderate to severe Cancer Related Pain (CRP) trials.
About the speaker — Walter Korz
Mr. Korz has over 35 years of multi-disciplinary life sciences experience gained in public healthcare and holding senior management positions with several emerging and established life sciences companies. Mr. Korz joined WEX in November 2010 and has a broad drug development background with significant experience in business development, finance, clinical development, regulatory affairs and project outsourcing.
Before WEX, Mr. Korz was Vice President, Drug Development and then President and CEO of Chemokine Therapeutics Corp. Mr. Korz was Clinical Development Manager with Angiotech Pharmaceuticals Inc. overseeing systemic therapy programs for rheumatoid arthritis, psoriasis, including one of Canada’s largest multiple sclerosis clinical trials. Much of his career was involved in cancer research during his service with AltaRex Corp and Biomira Research. where he was responsible for the development of therapeutic products, clinical trials, and regulatory filings.
Mr. Korz is a graduate from Southern Alberta Institute of Technology and the University of Saskatchewan and has a Masters of Business Administration from Athabasca University.
About the speaker — Abner Yong
Abner joined WEX Pharmaceuticals Inc. in March 2018 following over 15 years of corporate finance, treasury, accounting and transactions experience gained in an investment-grade multinational company and a Big 4 accounting firm. Prior to WEX, Abner held senior finance and accounting positions at Methanex Corporation, a Vancouver based NASDAQ/TSX listed multinational chemicals manufacturer and distributor, in corporate treasury and corporate accounting where he was responsible for financial operations, global budgeting, debt and credit financings, global treasury, SOX compliance and financial talent development. Prior to Methanex, Abner was with Ernst & Young in Transactions Advisory Services where he was engaged in numerous debt and credit financings, corporate restructurings and corporate transactions across Canada.
About ACCESS CHINA
ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations. View more information at https://biotochina.org/access-china-forum/
Register ACCESS CHINA online, please visit: ACCESS CHINA Biotech Forum
For more information, please contact: